Replies to post #33085 on Ocata Therapeutics Inc fka OCAT

[nmbr1stckpckr]

I woner if Cha's first injections will have more or the same level of RPE cells injected as in the US trials and whether the first patients' visions are as far gone as in the US trials. Since Cha is looking to complement their data with US data, I would hope that they are looking at a different larger dosage at least.

Also, I don't believe Cha's license for this therapy gives it exclusivity in Korea -- I think it was only for the blood cells.

[InvestorStemCell]

What a splendid article, well written and filled with great information. "Grin :)"

Disclosure: If ACT's hRPE cells attach to the Bruch's membrane in humans as they did in the Casey Eye Clinic Rats then a Optical coherence tomography (OCT) may yield a 10billion dollar Market cap?